Hualan Genetic

Hualan Genetic was established in 2013, focusing on the research and production of monoclonal antibody drugs. The company is mainly engaged in the production and development of monoclonal antibody drugs, recombinant human coagulation factor drugs, and hormone drugs. Hualan Genetic boasts a rich pipeline of products covering disease areas such as cancer, autoimmune diseases, diabetes, ophthalmology, and reproductive health. Its research and development portfolio ranges from biosimilar monoclonal antibodies to next-generation antibody technologies (such as bispecific antibodies and innovative heavy-chain antibody drugs), marking a development path that transitions from imitation to a combination of imitation and innovation, and finally to independent innovation. The company has built advanced and comprehensive drug R&D testing platforms, pilot workshops, large-scale production facilities, and quality control testing platforms. It operates four 2,500L and two 500L cell culture production lines designed according to EU and WHO standards, along with various fully automated filling lines capable of simultaneously handling the production, filling, encapsulation, and lyophilization of different product types and scales. Externally, it offers CRO and CMO services for biologics, including monoclonal cell line screening, evaluation, process development, drug analysis, formulation development, regulatory production, secondary packaging, labeling, and more.